XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Our study aims to compare the efficacy and safety of capecitabine and oxaliplatin for 4
months versus 6 months as adjuvant chemotherapy after D2 Gastrectomy in patients with gastric
cancer.
Hypothesis: For gastric patients after D2 Gastrectomy, capecitabine and oxaliplatin for 4
months show noninferiority to capecitabine and oxaliplatin for 6 months in disease-free
survival (DFS) and safety.